EVLO · Evelo Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.50M | $13.04M | $17.86M | - | $21.93M | $21.22M | $19.32M | - | $22.60M | $20.66M |
| SG&A | $3.89M | $4.92M | $7.04M | - | $7.13M | $8.37M | $9.42M | - | $10.11M | $7.00M |
| Total Operating Expenses | $11.18M | $19.57M | $24.90M | - | $29.05M | $29.59M | $28.74M | - | $32.71M | $27.66M |
| D&A | $500.0K | $400.0K | $445.0K | - | - | $500.0K | $517.0K | - | $600.0K | $500.0K |
| Operating Income | ($11.18M) | ($19.57M) | ($24.90M) | - | ($29.05M) | ($29.59M) | ($28.74M) | - | ($32.71M) | ($27.66M) |
| Interest Expense | $1.10M | - | - | - | - | - | - | - | - | - |
| Income Tax | ($17.0K) | $233.0K | $145.0K | - | $107.0K | $163.0K | $116.0K | - | $156.0K | $53.0K |
| Net Income | ($12.36M) | ($21.10M) | ($25.34M) | - | ($30.56M) | ($30.56M) | ($29.86M) | - | ($33.73M) | ($31.60M) |
| EPS - Basic | ($0.71) | ($3.78) | ($4.60) | - | ($5.60) | ($8.00) | ($11.00) | - | ($12.60) | ($12.60) |
| EPS - Diluted | ($0.71) | ($3.78) | ($4.60) | - | ($5.60) | ($8.00) | ($11.20) | - | ($9.00) | ($11.80) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.26M | $7.62M | $27.47M | $47.94M | $69.05M | $92.01M | $39.63M | $68.44M | $95.94M | $123.33M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $526.0K | $3.77M | $1.51M | $1.76M | $1.55M | $2.25M | $1.76M | $1.60M | $2.52M | $2.32M |
| Current Assets | $18.94M | $11.26M | $30.08M | $51.57M | $72.33M | $97.01M | $43.13M | $71.03M | $97.92M | $126.37M |
| Total Assets | $20.63M | $20.82M | $41.97M | $64.44M | $86.34M | $111.90M | $58.83M | $87.87M | $116.46M | $145.06M |
| Current Liabilities | $39.76M | $55.54M | $57.25M | $12.39M | $26.92M | $21.44M | $16.17M | $17.36M | $20.73M | $19.80M |
| Long-term Debt | $0 | $0 | $0 | $43.61M | $36.65M | $40.75M | $44.77M | $46.56M | $46.52M | $46.48M |
| Total Liabilities | $47.33M | $66.94M | $69.36M | $69.43M | $77.00M | $76.25M | $75.63M | $79.20M | $83.38M | $82.97M |
| Stockholders' Equity | ($26.71M) | ($46.13M) | ($27.39M) | ($4.99M) | $9.33M | $35.65M | ($16.80M) | $8.67M | $33.08M | $62.09M |
| Retained Earnings | ($588.03M) | ($575.67M) | ($554.56M) | ($529.22M) | ($505.68M) | ($475.12M) | ($444.56M) | ($414.69M) | ($386.04M) | ($352.31M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($20.28M) | - | - | - | ($28.93M) | - | - | - |
| Investing Cash Flow | - | - | ($12.0K) | - | - | - | ($153.0K) | - | - | - |
| Financing Cash Flow | - | - | ($199.0K) | - | - | - | $117.0K | - | - | - |
| CapEx | - | - | $12.0K | - | - | - | $153.0K | - | - | - |
| Free Cash Flow | - | - | ($20.29M) | - | - | - | ($29.09M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.80 | - | - | - | 0.97 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -59.9% | -101.4% | -60.4% | - | -35.4% | -27.3% | -50.8% | - | -29.0% | -21.8% |
| Return on equity | 46.3% | 45.8% | 92.5% | - | -327.4% | -85.7% | 177.7% | - | -102.0% | -50.9% |
| Return on invested capital | - | - | - | - | -49.9% | -30.6% | -81.2% | - | -32.5% | -20.1% |
| Liquidity | ||||||||||
| Current ratio | 0.48 | 0.20 | 0.53 | 4.16 | 2.69 | 4.52 | 2.67 | 4.09 | 4.72 | 6.38 |
| Quick ratio | 0.48 | 0.20 | 0.53 | 4.16 | 2.69 | 4.52 | 2.67 | 4.09 | 4.72 | 6.38 |
| Cash ratio | 0.43 | 0.14 | 0.48 | 3.87 | 2.57 | 4.29 | 2.45 | 3.94 | 4.63 | 6.23 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | -8.74 | 3.93 | 1.14 | -2.66 | 5.37 | 1.41 | 0.75 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.68 | 0.42 | 0.36 | 0.76 | 0.53 | 0.40 | 0.32 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -10.2x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.77 | -0.45 | -1.53 | -12.91 | 9.25 | 3.14 | -3.50 | 10.14 | 3.52 | 2.34 |
| Liabilities / Assets | 2.29 | 3.22 | 1.65 | 1.08 | 0.89 | 0.68 | 1.29 | 0.90 | 0.72 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | 483.9x | 89.6x | - | - | 227.4x | 236.2x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 61.5% | 33.8% | 13.4% | - | 11.2% | -7.0% | -4.6% | - | -62.1% | -36.6% |
| Net income growth (YoY) | 59.5% | 30.9% | 15.1% | - | 9.4% | 3.3% | -5.9% | - | -61.2% | -53.0% |
| EPS growth (YoY) | 87.3% | 52.8% | 58.9% | - | 37.8% | 32.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 30.2% | - | - | - | -9.4% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -63.0% | - | -71.8% | -42.6% | - | -71.6% | -34.4% | -10.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Evelo Biosciences against the 5 most active filers in the same SIC group.